Phase II Study to Evaluate the Tolerability and Efficacy of Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients With Hydroxychloroquine.

This is a single-center, open-label, single arm Phase 2 study evaluating the feasibility, and efficacy of treating CLL subjects with hydroxychloroquine. The study schema and schedule of events are as follows:

Prior to beginning hydroxychloroquine:

• Blood samples to be taken.
• Baseline tests confirming diagnosis of CLL as defined above (if not already obtained in records)
• Physical exam performed
• Either six months prior or 4 weeks within starting HCQ ophthalmologic exam documented
• Days 1-365 subject takes hydroxychloroquine 400mg/day
• At 2 weeks: CBC and chemistry
• Every 4 weeks: CBC, chemistry, history (including the inquiry about the presence or absence of visual symptoms) and physical exam.
• Starting at 4 weeks: blood samples taken for laboratory companion studies taken at office visit every 8 weeks.
• At 6 months (+ or - 30 days): subject will have follow up ophthalmologic exam). This will also be done in the presence of any visual/ocular symptoms.

All subjects must meet the selection criteria for registration in this study. All subjects must have a peripheral blood sample submitted. It is estimated that approximately 70 subjects will be screened. The anticipated accrual period is 12 months.